JNJ's Dual-targeting CAR T-cell Therapy Shows Encouraging First Results In Large B-cell Lymphoma
13/6 19:12
(RTTNews) - Johnson & Johnson (JNJ) announced the first clinical data from an ongoing Phase 1b study for JNJ-90014496 (JNJ-4496), an investigational dual-targeting anti-CD19/CD20 bispecific autologous chimeric antigen receptor (CAR) T-cell therapy, being studied in patients with...